Omniscient Neurotechnology Acquisition | Healthcare Deal in CA

Omniscient Neurotechnology has completed the acquisition of Omniscient Neurotechnology, a medical devices business in California, for $27.2 million. Omniscient Neurotechnology develops AI-enabled brain analysis and connectomics technology that produces patient-specific connectomic maps for language, movement, and cognition using its FDA-cleared Quicktome platform. The company’s platform supports clinical applications across brain computer interface (BCI), stroke, and movement disorders, aiming to improve neuro care outcomes and reduce neurologic complications. The healthcare M&A deal is structured as a platform acquisition and is part of a Series D funding round announced in San Francisco, with $27.2 million (AU$41.1 million) to scale commercialization and expand into high-growth markets.